Liquidia Technologies to receive $3 million in funding from NIST

Liquidia Technologies today announced it will receive approximately $3 million in funding from the U.S. Commerce Department’s National Institute of Standards and Technology (NIST) to further develop and scale-up the company’s PRINT manufacturing process. As part of its Technology Innovation Program (TIP), NIST announced it will fund new cost-sharing projects to support innovative technologies that address critical national needs.

“We are very excited to have been selected by NIST as one of the 20 projects to receive funding through the TIP program,” said Tom Templeman, Senior Vice President, Integrated Supply Chain at Liquidia. “This investment will support our continued development of PRINT manufacturing, which will allow us to develop clinically relevant quantities of particles for innovative vaccines and therapeutics.”

The PRINT manufacturing process uses a proprietary roll-to-roll method that allows Liquidia to produce precisely engineered particles, which offer safer and more efficient delivery of vaccine and therapeutic drug products. The capabilities realized as a direct result of this project will support the advancement of a platform of products, including the company’s initial vaccine product which is expected to enter clinical trials next year.

“As an industry, we are on the cusp of great therapeutic advancements in areas where unmet medical needs still persist,” said Neal Fowler, CEO of Liquidia Technologies. “An investment such as this plays a critical role in enabling Liquidia to advance innovative products to the next stage of development where we will begin to see the true potential for patients.”

http://www.liquidia.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing